ABSTRACT
Introduction Weil osteotomies are performed to surgically treat metatarsalgia, by shortening the metatarsal via either a single distal oblique cut (flat-cut) with translation of the metatarsal head, or through removal of a slice of bone (wedge-cut). The wedge-cut technique purportedly has functional and mechanical advantages over the flat-cut procedure, however in-vivo data and quality of evidence is currently lacking. This study aims to investigate whether wedge-cut Weil osteotomy compared to traditional flat-cut Weil is associated with increased pain relief and fewer complications up to 12 months postoperatively.
Methods and analysis Patient, surgical and clinical data will be collected for 80 consecutive consenting patients electing to undergo surgical treatment of propulsive metatarsalgia in a randomised control trial, embedded within a clinical registry. The primary outcome is patient-reported pain as assessed by the Foot and Ankle Outcome Score (FAOS) - Pain subscale, and the secondary outcome is the incidence of procedure-specific complications at up to 12 months postoperatively. The groups will be randomised using a central computer-based simple randomisation system, with a 1:1 allocation without blocking and allocation concealment. A mixed-effects analysis of covariance will be used to assess the primary outcome, with confounders factored into the model. A binary logistic regression will be used to assess the secondary outcome in a multivariable model containing the same confounders.
Trial registration Australian New Zealand Clinical Trials Registry, ACTRN12620001251910. Registered on 23 November 2020.
Ethics and dissemination Ethics approval for this study was provided through the NSW/VIC branch of the Ramsay Health Care Human Research Ethics Committee (HREC approval number 2020-007). The results of this study will be disseminated through peer-reviewed journals and conference presentations.
Strengths and limitations of this study
To the best of the authors knowledge, the trial will be the first to examine clinical efficacy of the wedge-cut Weil osteotomy compared to the flat-cut technique with a prospective, randomised control design.
A sample size of N=80 participants will ensure adequate power to detect differences between the control and experimental groups, with an allowance for a dropout rate of 10%.
A limitation in the methods is the routine performance of adjunct surgical procedures for lesser toe or soft tissue correction. The statistical plan aims to control for this by treating adjunct procedures as potential confounders of the effect of the intervention, along with prognostic factors identified from available literature on pain ratings in metatarsalgia. These confounders will be included in the models used to analyse the primary and secondary outcomes.
Competing Interest Statement
AW and MS are the investigator-sponsors for the trial, and will be jointly responsible for its funding and governance. AW declares institutional funding and fellowship payments from Zimmer Biomet and DePuy Synthes, for facilitating teaching workshops. AW and MS have employed EBM Analytics to assist with trial conduct and management. CS is a shareholder and paid employee of EBM Analytics, and in the last three years has received institutional payments from Exactech Inc., Stryker South Pacific, Headsafe Pty Ltd and Naviswiss AG for work unrelated to this clinical trial or the primary investigators. CS is a past Associate Editor for the Journal of Orthopaedic Surgery and Research. MF and NE are paid employees of EBM Analytics.
Clinical Trial
ACTRN12620001251910
Funding Statement
AW and MS are the investigator-sponsors for the trial, and will be jointly responsible for its funding and governance. AW and MS have employed EBM Analytics to assist with trial conduct and management.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ramsay Health Care Human Research Ethics Committee (HREC approval number 2020-007)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
N/A
